

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number
WO 03/035046 A2

(51) International Patent Classification⁷: **A61K 31/00**

(21) International Application Number: PCT/EP02/11652

(22) International Filing Date: 17 October 2002 (17.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/330,337 18 October 2001 (18.10.2001) US

(71) Applicant (for all designated States except AT, US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BÜHLMAYER, Peter** [CH/CH]; Hangstrasse 18, CH-4144 Arlesheim (CH). **WEBB, Randy, Lee** [US/US]; 17 Honeyman Drive, Flemington, NJ 08822 (US).

(74) Agent: **GROS, Florent**; NOVARTIS AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ORGANIC COMPOUNDS

(57) Abstract: The invention relates to a salt formed of at least one AT₁-receptor antagonist having at least one acidic center and of at least one cardiovascular ingredient having at least one basic center that can be used for treating cardiovascular diseases and conditions, their prophylaxis or delay of progression.



WO 03/035046 A2

Organic Compounds

This invention relates to salts formed of an AT₁-receptor antagonist and a cardiovascular ingredient, pharmaceutical compositions thereof and methods of using said salts to treat patients suffering from cardiovascular diseases and related conditions.

As cardiovascular diseases are leading causes of death in industrialised countries and as the majority of affected patients are middle aged, there exists an increasing need for potent as well as easily administered drugs for the therapy of cardiovascular diseases.

Under the term cardiovascular diseases and related conditions commonly used in the art as a generic term may be summarized diseases or conditions such as e. g. hypertension, congestive heart failure, post myocardial infarction, angina pectoris, coronary heart diseases, cardiac arrhythmia, atherosclerosis, endothelial dysfunction, renal diseases, e.g. acute and preferably chronic renal disease, isolated systolic hypertension, peripheral vascular disease, hyperlipidemia, stroke or end-organ damage. Although drug classes as well as their combinations for the treatment of said diseases and related conditions are well known and commonly used, the patient compliance is often reduced due to the complex therapeutic schemes and the high intake rates.

The present invention provides a unique concept, which is an alternative to fixed combinations. For the first time, combination salts of at least one AT₁ receptor antagonist with at least one further basic cardiovascular active principle (ingredient) have been made. In a fixed combination, different active principles are separately combined in a dosage unit form. In a conventional fixed combination, acidic or basic active ingredients may react within the dosage unit form with pharmaceutical auxiliaries and additives, e.g. by forming esters and the like. A prolonged storage of corresponding dosage unit forms may result in an increased amount of side products. A dosage unit form comprising a combination salt formed of at least two active principles is more stable and resistant to forming unwanted side products. Furthermore, combination salts according to the present invention have improved properties. Corresponding improved properties comprise suitable and improved therapeutic activities and pharmacodynamic effects. For example, the beneficial effects of a combination salt formed of at least two active principles comprises a broader therapeutic applicability, a potentiation or synergism of the activity of one of the salt components, an enhancement of the pharmacodynamic properties. A combination salt can also be used to

achieve therapeutic effects even at sub-therapeutic amounts of at least one active principle within a corresponding combination salt.

Accordingly, the invention provides salts formed of at least one AT₁-receptor antagonist having at least one acidic center and of at least one cardiovascular ingredient having at least one basic center.

The term "at least one" whenever referred to herein may define one, two or more units.

The term "acidic center" whenever referred to herein means a functional group able to split of a proton e.g. the hydrogen atom of the carboxyl group, of the sulphonamide group or that of the tetrazole ring of the AT₁-receptor antagonist.

The term "basic center" whenever referred hereinto means a functional group able to gain a proton, for example, the basic amino function in e.g. alkylamines, such as ?? ,or any basic heterocycles, such as pyridines, pyrazines, or piperidines.

The term "patient" whenever referred to herein means mammals including humans.

The term "additive effect" or "synergistic effect", respectively, whenever referred to herein, for example, may be defined using the following equations:

$a/A + b/B = 1$ means an additive effect

$a/A + b/B < 1$ means a synergistic or superadditive effect,

where "A" and "B" are equieffective doses of the individual ingredients when each is present alone; "a" and "b" are the respective doses in the salt according to the invention that give the effect level achieved by dose "A" alone or dose "B" alone. Reference is made to R.J.

Tallarida. "Statistical analysis of drug combinations for synergism", Pain 1992; 49:93-97 and "Drug synergism and dose-effect data analysis", Editor, R.J. Tallarida, Chapman and Hall/CRC, New York, 2000.

It is expected that in the case of the salts according to the invention, effects will be assessed e.g. as changes in blood pressure and more specifically, as antihypertensive effects.

Therefore, the two ingredients forming a salt according to the invention would be synergistic when their effects are greater than that expected from the sum of the individual ingredients, especially at the same doses as in the salt. The hypothesis to be tested is that the two active ingredients are additive when given together. If they are not additive, then an

interaction has occurred that may result e.g. in a superadditive response. With a careful experimental design, this can be assessed using appropriate statistical methods as referenced above, e.g. corresponding effects can be taken from dose-response-curves.

In addition to blood pressure, the measurements of heart rate or neurohormones (plasma renin activity, aldosterone or norepinephrine) may also be used to determine the relationship between the salt and their individual component drugs.

Finally, the determination of plasma levels of each component of the salt can also be used to indicate a response, for example, additive or synergistic, that is different from that of the component parts. It is understood that a direct relationship exists between the amount of drug in the plasma and the pharmacologic effect induced by the drug. Therefore, drug levels of the component drugs contained within the salt can be used, either alone or in conjunction with the pharmacodynamic response to demonstrate an advantage of the salt formulation over that of individual components of the salt.

The term "potentiation" shall mean an enhancement of a corresponding pharmacological activity or therapeutic effect, respectively. Potentiation of one component within the combination salt according to the present invention formed with another component within the combination salt according to the present invention means that an effect is being achieved that is greater than that achieved with one component alone.

The term "synergistic effect" or "effect of "potentiation" is used in the context of this application to mean an enhanced responsiveness to the drug. For example, if the salts according to the invention result in an improvement in the absorption, with an increase in the plasma concentration of the AT₁-receptor blocker then the extent of e.g. blood pressure lowering may be "potentiated" or greater than expected.

The pharmacodynamic properties of one active principle within the combination salt of the present invention can also be potentiated by the further active principle within the combination salt of the present invention leading to synergism or potentiation.

The term "AT₁-receptor antagonist" (also called Angiotensin-II-receptor antagonist) whenever referred hereinto has to be understood to define those active ingredients that bind to the

AT₁-receptor subtype of Angiotensin-II but do not result in an activation of the receptor and prevent activation of the receptor by Angiotensin-II.

The term "cardiovascular ingredient" whenever referred hereinto means an ingredient selected from the group consisting of calcium channel blockers, endothelin antagonists, renin inhibitors, beta-blockers, alpha-adrenergic antagonists and alpha-adrenergic agonists.

The class of AT₁-receptor antagonist comprises compounds having differing structural features, essentially preferred are the non-peptidic ones. For example, mention may be made of the compounds that are selected from the group consisting of valsartan which is disclosed in EP 443 983, losartan disclosed in EP 253 310, candesartan disclosed in EP 459 136, eprosartan disclosed in EP 403 159, irbesartan disclosed in EP 454 511, olmesartan disclosed in EP 503 785, tasosartan disclosed in EP 539 086 and telmisartan disclosed in EP 522 314, all of which are incorporated herein by reference.

Preferred AT₁-receptor antagonists are those agents that have been marketed, most preferred is valsartan.

Calcium channel blockers (CCBs) are known to those skilled in the art. Examples of CCBs useful for the salts of the invention are preferably dihydropyridine representatives selected from the group consisting of amlodipine, nitrendipine, nimodipine, nicardipine, nisoldipine, felodipine, isradipine and nifedipine.

Preferred calcium channel blockers are those agents that have been marketed, most preferred is amlodipine disclosed in EP 89167, especially the besylate or maleate thereof.

Endothelin antagonists are highly specific competitive inhibitors of endothelin and modifications of the molecule itself. The endothelin receptors can be subdivided in type A and type B. Most of the endothelin antagonists have an affinity for both receptor types. An example of an endothelin antagonist useful for the salts of the invention is preferably tezosentan.

Renin inhibitors have enzyme-inhibiting properties and inhibit in particular the action of the natural enzyme renin. As a result a smaller amount of Angiotensin-II is produced whose reduced concentration is the direct cause of the antihypertensive effect of renin inhibitors.

An example of a renin inhibitor useful for the salts of the invention is preferably (2S,4S,5S,7S)-5-amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonansäure (2-carbamoyl-2-methyl-propyl)-amid disclosed in EP 678503 and incorporated herein by reference. Especially preferred is the hemi-fumarate salt thereof.

Beta-blockers are known in the art. A beta blocker preferably is a representative selected from the group consisting of a selective β 1-blocker, such as atenolol, bisoprolol (especially the fumarate thereof), metoprolol (especially the hemi-(R,R)fumarate or fumarate thereof), furthermore, acebutolol (especially the hydrochloride thereof), esmolol (especially the hydrochloride thereof), celiprolol (especially the hydrochloride thereof), taliprolol, or acebutolol (especially the hydrochloride thereof), a non-selective β -blocker, such as oxprenolol (especially the hydrochloride thereof), pindolol, furthermore, propanolol (especially the hydrochloride thereof), bupranolol (especially the hydrochloride thereof), penbutolol (especially the sulphate thereof), mepindolol (especially the sulphate thereof), carteolol (especially the hydrochloride thereof) or nadolol, and a β -blocker with α -blocking activity such as carvedilol; or in each case, a pharmaceutically acceptable salt thereof. Preferred examples of beta-blockers useful for the salts of the invention are especially beta-blockers that have been marketed preferably carvedilol, oxprenolol, propanolol and metoprolol. Most preferred is oxprenolol.

Alpha-adrenergic antagonists are known in the art. Examples of alpha-adrenergic antagonists useful for the salts of the invention are preferably terazosin disclosed in US4026894 and metazosin disclosed in US 4775673.

Alpha-adrenergic agonists are known in the art. An example of an alpha-adrenergic agonist useful for the salts of the invention is preferably moxonidine disclosed in US 4323570.

The structure of the active agents identified by generic names may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g. (LifeCycle) Patents International (e.g. IMS world Publications). The corresponding content thereof is hereby incorporated by reference. Any person skilled in the art is fully enabled to identify the active agents and, based on these references, likewise enabled to manufacture and test the pharmaceutical indications and properties e.g. in standard test models, both in vitro and in vivo.

Representative studies are carried out with a salt formed of valsartan and amlodipine, e.g. applying the following methodology. All experiments are performed in spontaneously hypertensive rats (SHR) supplied by Taconic Farms, Germantown, New York (Tac:N(SHR)fBR). A radiotelemetric device (Data Sciences International, Inc., St. Paul, Minnesota) is implanted into the lower abdominal aorta of all test animals between the ages of 14 to 16 weeks of age. All SHR are allowed to recover from the surgical implantation procedure for at least 2 weeks prior to the initiation of the experiments. The radiotransmitter is fastened ventrally to the musculature of the inner abdominal wall with a silk suture to prevent movement. Cardiovascular parameters are continuously monitored via the radiotransmitter and transmitted to a receiver where the digitized signal is then collected and stored using a computerized data acquisition system. Blood pressure (mean arterial, systolic and diastolic pressure) and heart rate are monitored in conscious, freely moving and undisturbed SHR in their home cages. The arterial blood pressure and heart rate are measured every 10 minutes for 10 seconds and recorded. Data reported for each rat represent the mean values averaged over a 24 hours period and are made up of the 144-10 minute samples collected each day. The baseline values for blood pressure and heart rate consist of the average of three consecutive 24 hours readings taken prior to initiating the drug treatments. All rats are individually housed in a temperature and humidity controlled room and are maintained on a 12 hour light/dark cycle. See also, Webb et al., J. Hypertens., 1998; 16(6): 843-52.

Drugs are administered either at a single dose by oral gavage or with repeated daily administration. Oral dosages of the individual agents may vary but typically will be in the range of for example: valsartan (0.3 – 30.0 mg/kg/day); amlodipine (1-10 mg/kg/day); renin inhibitor (10-100 mg/kg/day); other agents will be given at appropriate concentrations according to their known pharmacological properties and will often be tested at sub-maximally effective dosages in order to observe any expected potentiation of response. For example, the degree to which blood pressure can be reduced is a function of the extent to which various physiological control systems are activated but is ultimately limited by homeostatic mechanisms that protect against shock. Agents given as the monotherapy are administered at less than maximally effective dosages. Consequently, when salts according to the invention formed of at least one AT₁-receptor antagonist and for example, of at least one CCB are given, a further antihypertensive effect can be achieved. The potential for an enhancement of the antihypertensive effect or a synergistic action can then be

demonstrated. Furthermore, synergy can be observed as actions other than those on blood pressure. Salts according to the invention with distinctive mechanisms of action have complementary effects. For example, alpha adrenergic antagonists and CCBs can evoke stimulation of the renin angiotensin or sympathetic nervous systems resulting in an increase in heart rate. When a salt according to the invention is given, blockade of the AT₁-receptor can prevent the activation of compensatory cardiovascular reflexes and thereby attenuate an increase in heart rate. While this beneficial response can occur when both agents are administered as individual components, the effect is greatest when a salt according to the invention is used. A salt according to the invention could result in better absorption of both components, a more rapid absorption and/or a more complementary peak plasma concentration of both components. The overlap of peak plasma concentrations of the AT₁-receptor antagonist and the cardiovascular ingredient would enable the AT₁-receptor blocker to minimize the negative or detrimental effects of the cardiovascular ingredient.

Following either single or repeated administration of the test substances, the animal are sacrificed and tissues removed for further analysis. For example, to assess endothelial function, blood vessels can be removed and vasoconstriction and/or vasodilation to various substances can be determined. Typical methods are described by Shetty et al., *Biochem. Biophys. Res. Commun.* 1993; 191(2): 459-64.

Effects on end-organ damage can best be observed with repeated, chronic dosing. Methods are described by Webb et al., *Clin. Exp. Hypertens.* 1998; 20(7): 775-93. In these types of studies, effects on renal and cardiac function can be monitored. Histological effects on organ structure can also be determined.

The salts according to the invention result not only in a beneficial, especially potentiation or a synergistic, therapeutic effect, but also in additional benefits such as a surprising prolongation of efficacy, a broader rate of response to therapeutic treatment and surprising beneficial effects on diseases and conditions as specified herein. Normal mammalian systems have a strong capacity to buffer or attenuate the antihypertensive effects resulting from interruption of a single blood pressure regulatory system. Thus, the targeting of two systems simultaneously might provide superior blood pressure control. A salt according to the invention would allow multiple blood pressure regulatory systems to be targeted simultaneously. More effective blood pressure control and less activation of detrimental

compensatory responses thus result. This can be demonstrated as an attenuation of heart rate, less cardiac stimulation, improved blood flow to organs, and less activation of vasoactive hormones such as angiotensin, norepinephrine and aldosterone. Any of these effects can be additive or synergistic and ultimately preserve organ function more effectively. Further surprising beneficial effects are e.g. reduction of side effects compared to a monotherapy applying only one of the pharmaceutically active compounds used in the salts disclosed herein.

The good physicochemical properties of the salts according to the invention give the possibility of attaining economic advantages by enabling simpler process steps to be carried out during working up. This is also of great importance to the quality of the active substance and its galenic forms during production, storage and administration to the patients. The salts according to the invention show good stability and quality properties also during storage and distribution.

This invention is directed to salts formed of at least one AT₁ receptor antagonist having at least one acidic center and of at least one cardiovascular ingredient having at least one basic center.

This invention is particularly directed to salts where the AT₁ receptor antagonist is valsartan. Further the invention is directed to salts where the cardiovascular ingredients are selected from the group consisting of calcium channel blockers, endothelin antagonists, renin inhibitors, beta-blockers, alpha-adrenergic antagonists and alpha-adrenergic agonists. More specifically, a salt where the cardiovascular ingredient is selected from the group consisting of amlodipine, oxprenolol and (2S,4S,5S,7S)-5-amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonansäure (2-carbamoyl-2-methyl-propyl)-amid.

This invention is still more particularly directed to salts formed of valsartan and amlodipine, valsartan and oxprenolol and valsartan and (2S,4S,5S,7S)-5-amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonansäure (2-carbamoyl-2-methyl-propyl)-amid.

The molar ratio of the AT₁ receptor antagonist to the cardiovascular ingredient within the combination salts can vary and is dependent on the number of acidic and basic centers. For illustration, if the AT₁ receptor antagonist has two acidic centers and the cardiovascular

ingredient has one basic center, the molar ratio of corresponding combination salts will be 1:1 and 2:1.

The molar ratio of the AT₁ receptor antagonist to the cardiovascular ingredient of the salts according to the invention is especially 1:1(, 2:1) or 1:2. E.g. in the case where an AT₁ receptor antagonist such as valsartan having two acidic centers is selected for the formulation of the salts according to the invention the molar ratio of AT₁ receptor antagonist to cardiovascular ingredient can be 1:1 or 1:2.

The salts according to the invention exist in a form selected from the group consisting of a crystalline form, partly crystalline form and polymorphous form. The salts according to the invention exist also in amorphous form.

Additionally the salts according to the invention occur as a solvate e.g. a hydrate. Said solvates and hydrates are also within the scope of this invention.

The combination salts according to the present invention can also be combined with a diuretic. The diuretic is preferably selected from the group consisting of bumetanide, ethacrynic acid, furosemide, torsemide, amiloride, spironolactone, eplerenone, triamterene, chlorothalidone, chlorothiazide, hydrochlorothiazide (HCTZ), hydroflumethiazide, methylchlorothiazide, metolazone, and dichlorphenamide. Diuretics may be understood in three classes: thiazides (e.g., HCTZ), potassium sparing (e.g., triamterene, spironolactone) and "loop" diuretics (e.g., furosemide). The most preferred diuretic for the intended combination is a thiazide diuretic, e.g. hydrochlorothiazide.

The daily dosage of the diuretic to be combined with the combination salt according to the inventive present combination is between 5 and 200 mg, preferably between 5 and 100 mg and more preferably between 5 and 50 mg.

In a variation thereof, the present invention likewise relates to a "kit-of-parts", for example, in the sense that the components (combination salt and diuretic) to be combined according to the present invention can be dosed independently or by use of different fixed combinations with distinguished amounts of the components, i.e. simultaneously or at different time points. The parts of the kit of parts can then e.g. be administered simultaneously or chronologically staggered, that is at different time points and with equal or different time intervals for any part of the kit of parts. Preferably, the time intervals are chosen such that the effect on the

treated disease or condition in the combined use of the parts is more beneficial than the effect that would be obtained by use of only any one of the components.

A further object of the invention is the preparation of the salts according to the invention. Accordingly, one of the components is dissolved in an appropriate reaction inert solvent. In the next step, said solution is added to a solution of the other component and the resulting salt is isolated, e.g. by evaporation or by the addition of a less polar solvent. Specifically, a salt of the invention is prepared e.g. by dissolving the free base of a cardiovascular ingredient in an appropriate reaction inert solvent (e.g. an ether, e.g. tetrahydrofuran, diethylether or dioxan, a nitrile, e.g. acetonitrile, a halogenated hydrocarbon, e.g. chloroform or methylenechloride, an ester, e.g. ethylacetate, an alcohol, e.g. ethanol, methanol or isopropanol or a hydrocarbon, e.g. pentane, hexane or petroleum ether) and adding the resulting solution to a solution of the free acid of the AT₁ receptor antagonist in an appropriate reaction inert solvent. As used herein, the expression "reaction inert solvent" and "inert solvent" refer to a solvent or mixture of solvents which does not interact with starting materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product. The reaction mixture is stirred vigorously at ambient or elevated temperature. Crystallization is accomplished by the addition of less polar solvents to afford the salts according to the invention.

Accordingly the pK_a-value of the cardiovascular ingredient useful for the preparation of a salt according to the invention is ≥ 7 .

The invention provides also pharmaceutical compositions comprising a salt according to the invention.

The salts according to the invention may be used e.g. in a therapeutically effective amount, optionally together with a pharmaceutically acceptable carrier, for example with an inorganic or organic, solid or optionally also liquid pharmaceutically acceptable carrier, which is suitable for enteral, e.g. rectal, oral or parenteral administration. Although the preferred mode of administration of the compounds of this invention is oral, they may be administered parenterally (subcutaneous, intramuscular, intravenous, transdermal) as well.

The excipients used may be those known in the art for example as described in Remington's Pharmaceutical Sciences, 19th Ed. and Handbook of Pharmaceutical Excipients, or

analogous to those known in the art or new excipients having analogous function to those described in the art.

In so far as the procedures for formulation are not described herein such formulation procedures may for example be known in the art, or analogous to those known in the art. Representative procedures are disclosed in for example, Remington's Pharmaceutical Sciences, 19th Ed., Mack Publ., Co., 1995, H. Sucker et al and L. Lachman et al. The Theory and Practice of Industrial Pharmacy, 3rd Ed, 1986 as well as later editions, the contents of all of which are incorporated herein by reference.

The invention provides also pharmaceutical compositions for the treatment of cardiovascular diseases.

The invention provides further the use of a salt according to the invention in the preparation of a medicament for the prophylaxis, the treatment or delay of progression of cardiovascular diseases and conditions.

In another aspect the invention provides a method of treating cardiovascular diseases and conditions related thereto, their prophylaxis or delay of progression comprising administering to a patient in need thereof an effective amount of a salt according to the invention.

It is a fact that cardiovascular diseases, like most diseases, never remain stable. Cardiovascular diseases, if untreated or improperly treated, will progressively worsen with time. High blood pressure is a surrogate marker for underlying cardiovascular disease. The high blood pressure per se exerts an undue stress on blood vessels throughout the body and over time results in further damage to blood vessels and tissues. Chronic antihypertensive treatment will delay or slow the progression of cardiovascular disease by attenuating the rise in blood pressure. If the blood pressure is not reduced, it will lead to structural adaptation in the vasculature (fibrosis, cell necrosis) with stiffening of blood vessels and ultimately to a reduction in blood flow to the vital organs (kidney, heart, brain). It has been shown that chronic antihypertensive therapy effectively reduces the incidence of stroke, cardiac and renal disease.

It is unlikely that treatment would be initiated in a patient with normal blood pressure. However, a patient that is diagnosed with hypertension can be treated with the intent to reduce the elevated blood pressure. In so doing, this treatment can be considered

prophylactic for the prevention of subsequent cardiovascular events such as stroke, heart failure and kidney failure. Therefore, it is important to identify hypertension at an early stage and to begin treatment immediately. Early initiation of treatment in hypertensive patients, at a time point when no cardiovascular damage has yet occurred, will be an effective prophylaxis.

The dosage of active salt administered is dependent on the body weight, age, individual condition, and on the form of administration. The dosage amount necessary to achieve the desired therapeutic effect is within the skill of those who practice in the art having the benefit of the disclosure herein.

It is expected that if the salt results in an improvement in the bioavailability of the substances or in an improved pharmacokinetic pattern between the two components, then a reduced dosage of the components will be required over that of the case when both components are administered separately. For example, the AT₁-receptor blocker, when given as a salt according to the invention, may be administered at a dose that would preferably be considered submaximal if it were given alone. It may be expected that a dosage of 3-10 mg/kg of the AT₁-receptor blocker, e.g. valsartan and a corresponding (equi)molar amount of a CCB, e.g. amlodipine, when given as a salt according to the invention would be required to achieve a significant effect on blood pressure whereas a dosage of 10-30 mg/kg of the AT₁-receptor blocker, e.g. valsartan, would be required when administered separately. It is well known that CCBs have demonstrable dose-related side effects and thus it would be anticipated that less side effects can be observed if a lower dose is given while still maintaining the beneficial pharmacological actions.

Further surprising beneficial effects are e.g. reduction of side effects compared to a monotherapy applying only one of the pharmaceutically active compounds used in the salts disclosed herein.

The following examples illustrate the above-described invention; however, it is not intended to restrict the scope of this invention in any manner.


Working Example 1

Salt prepared from one equivalent of the AT₁ receptor antagonist, valsartan, (component A) and two equivalents of the cardiovascular ingredient, the renin inhibitor (2S,4S,5S,7S)-5-

amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonansäure (2-carbamoyl-2-methyl-propyl)-amid, (component B)

536 mg of component B (Fumarat) are dissolved in 60 ml of methylenchloride and transferred into the free base by extraction with 15 ml of 2N aqueous sodium hydroxide. The organic phase is washed with water and brine, dried over sodium sulfate and evaporated in vacuo. Drying of the residue in high vacuo (room temperature, 30 minutes) renders the free base component B (444mg, 0.804mMol, MG 551.8). This material is dissolved in 20ml methylenchloride and treated with 175 mg of component A (0.402mMol, MG 435.5). The mixture is stirred at room temperature for two hours and then evaporated to dryness. The residue is dissolved in 6 ml of tetrahydrofuran and the solution is added dropwise to 100 ml of hexane (precipitation). Filtration and drying in high vacuo for 72 hours at room temperature gives the product as a colorless powder.

MS (M+H)⁺ 436.2 (A) und 552.3 (B).



Ratios:

	Ratio of the components	calculated	Experiment *)
Example 1	A : B	1 : 2	1 : 1.88

*) as determined by Area under the curve by HPLC


Elementary analysis (found): C 65.50; H 8.48; N 10.94; O 15.33; water 0.46.

Working Example 2

Salt prepared from one equivalent of component A and one equivalent component B

300 mg of component B (0.544 mMol, MG 551.8) received by extraction of a solution of 350 mg of the fumarate in methylenchloride with 1N aqueous of sodium hydroxide are dissolved in a small amount of ethylacetate and treated with und 237 mg of component A (0.544 mMol, MG 435.5). When complete dissolution is achieved the salt product is precipitated by adding petroleum ether. Ultrasonification and scratching yields homogenized material that can be isolated by filtration. Drying in high vacuo overnight at room temperature gives the product as a white powder. MS (M+H)⁺ 436.2 (A) und 552.3 (B).

Melting point ca. 115°C (dec.).



Ratios:

	Ratio of the components	calculated	Experiment *)
Example 2	A : B	1 : 1	1 : 1.03

*) as determined by Area under the curve by HPLC

The following salts can be prepared in a manner as described in Working Examples 1 or 2:

Working Examples 3-6:

Salt prepared from one equivalent of component A and two equivalents of oxprenolol;
elementary analysis (found): C 66.77; H 7.86; N 10.01; O 15.31; water 0.11.

Salt prepared from one equivalent of component A and one equivalent of oxprenolol,
elementary analysis (found): C 66,47; H 7.59; N 11.95; O 14.24; water 0.5.

Salt prepared from one equivalent of component A and two equivalents of amlodipine;
elementary analysis (found): C 60.98; H 6.45; N 9.75; Cl, 5.57; O 17.25; water 0.56.

Salt prepared from one equivalent of component A and one equivalent of amlodipine, elementary analysis (found): C 62.03; H 6.56; N 11.17; Cl 4.22; O 15.82; water 0.42.

Formulation Example 1:

Tablets, each containing 50 mg of a salt of the invention, for example a salt formed of valsartan and (2S,4S,5S,7S)-5-amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonansäure (2-carbamoyl-2-methyl-propyl)-amid, can be prepared as follows:

Composition (for 10,000 tablets)

Active ingredient	500.0 g
Lactose	500.0 g
Potato starch	352.0 g
Gelatin	8.0 g
Talc	60.0 g
Magnesium stearate	10.0 g
Silica (highly disperse)	20.0 g
Ethanol	q.s.

The salt of the invention is mixed with the lactose and 292 g of potato starch, and the mixture is moistened using an alcoholic solution of the gelatin and granulated by means of a sieve. After drying, the remainder of the potato starch, the talc, the magnesium stearate and the highly disperse silica are admixed and the mixture is compressed to give tablets of weight 145.0 mg each and salt content of 50.0 mg which, if desired, can be provided with breaking notches for finer adjustment of the dose.

Formulation Example 2:

Coated tablets, each containing 100 mg of a salt of the invention, for example a salt formed of valsartan and (2S,4S,5S,7S)-5-amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonansäure (2-carbamoyl-2-methyl-propyl)-amid, can be prepared as follows:

Composition (for 1000 tablets):

Active ingredient	100.00 g
Lactose	100.00 g
Corn starch	70.00 g
Talc	
Calcium stearate	1.50 g
Hydroxypropylmethylcellulose	2.36 g
Shellac	0.64 g
Water	q.s.
Dichloromethane	q.s.

The salt of the invention, the lactose and 40 g of the corn starch are mixed and moistened and granulated with a paste prepared from 15 g of corn starch and water (with warming). The granules are dried, and the remainder of the corn starch, the talc and the calcium stearate are added and mixed with the granules. The mixture is compressed to give tablets (weight: 280 mg) and these are coated with a solution of the hydroxypropylmethylcellulose and the shellac in dichloromethane (final weight of the coated tablet: 283 mg).

Formulation Example 3:

Tablets and coated tablets containing a salt of the invention, for example as in one of Working Examples 1-6, can also be prepared in an analogous manner to that described in Formulation Examples 1 and 2.

CLAIMS

1. A salt formed of at least one AT₁-receptor antagonist having at least one acidic center and of at least one cardiovascular ingredient having at least one basic center.
2. A salt according to claim 1 where the AT₁-receptor antagonist is valsartan.
3. A salt according to claim 1 where the cardiovascular ingredient is selected from the group consisting of calcium channel blockers, endothelin antagonists, renin inhibitors, beta-blockers, alpha-adrenergic antagonists and alpha-adrenergic agonists.
4. A salt according to any one of claims 1 to 3 where the cardiovascular ingredient is selected from the group consisting of amlodipine, oxprenolol and (2S,4S,5S,7S)-5-amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonansäure (2-carbamoyl-2-methyl-propyl)-amid.
5. A salt according to claim 4 selected from the salts formed of valsartan and amlodipine, valsartan and oxprenolol and valsartan and (2S,4S,5S,7S)-5-amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonansäure (2-carbamoyl-2-methyl-propyl)-amid.
6. A salt according to claim 5 where the molar ratio of AT₁-receptor antagonist to cardiovascular ingredient is 1:1 or 1:2 .
7. A salt according to claim 1 in a form selected from the group consisting of a crystalline form, partly crystalline form, amorphous form and polymorphous form.
8. A salt according to claim 7 which is in the form of a solvate or hydrate.
9. A process for the manufacture of a salt according to claim 1 characterized in that a solution of an AT₁-receptor antagonist is mixed with a solution of a cardiovascular ingredient and the resulting salt is isolated.
10. A pharmaceutical composition comprising a salt according to claim 1 and a pharmaceutically acceptable carrier.

11. A method of treating cardiovascular diseases and conditions, their prophylaxis or delay of progression comprising administering to a patient in need thereof an effective amount of a salt according to claim 1.
12. Use according to claim 11 for the prophylaxis, treatment or delay of progression of cardiovascular diseases and conditions selected from the group consisting of hypertension, congestive heart failure, post myocardial infarction, angina pectoris, coronary heart diseases, cardiac arrhythmia, atherosclerosis, endothelial dysfunction, renal disease, acute renal disease, chronic renal disease, isolated systolic hypertension, peripheral vascular disease, hyperlipidemia, stroke and end-organ damage.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number
WO 03/035046 A3

- (51) International Patent Classification⁷: **A61K 31/41**, 31/4422, A61P 9/00
- (74) Agent: **GROS, Florent**; NOVARTIS AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).
- (21) International Application Number: PCT/EP02/11652
- (22) International Filing Date: 17 October 2002 (17.10.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/330,337 18 October 2001 (18.10.2001) US
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR).
- (71) Applicant (*for all designated States except AT, US*): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- Published:
— with international search report
- (71) Applicant (*for AT only*): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).
- (88) Date of publication of the international search report:
24 December 2003
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **BÜHLMAYER, Peter** [CH/CH]; Hangstrasse 18, CH-4144 Arlesheim (CH). **WEBB, Randy, Lee** [US/US]; 17 Honeyman Drive, Flemington, NJ 08822 (US).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 03/035046 A3

(54) Title: SALTS FORMED OF AN AT₁-RECEPTOR ANTAGONIST AND A CARDIOVASCULAR AGENT

(57) Abstract: The invention relates to a salt formed of at least one AT₁-receptor antagonist having at least one acidic center and of at least one cardiovascular ingredient having at least one basic center that can be used for treating cardiovascular diseases and conditions, their prophylaxis or delay of progression.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 02/11652

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/41 A61K31/4422 A61P9/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00 02543 A (NOVARTIS ERFIND VERWALT GMBH ;NOVARTIS AG (CH); GASPARO MARC DE (C) 20 January 2000 (2000-01-20) page 1, paragraph 1 -page 2, paragraph 3 claims 1-10 page 3, paragraphs 4,6 page 4, line 1-4 page 5, paragraph 5 page 6, paragraph 2 page 8, paragraph 2	1-12
Y	WO 00 44378 A (NOVARTIS ERFIND VERWALT GMBH ;NOVARTIS AG (CH); ODDOU PASCALE (CH)) 3 August 2000 (2000-08-03) claims 1-9	10-12
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

26 June 2003

Date of mailing of the international search report

03/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bazzanini, R

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/11652

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, Y	WO 02 40007 A (NOVARTIS ERFIND VERWALT GMBH ; VASELLA DANIEL LUCIUS (CH); NOVARTIS) 23 May 2002 (2002-05-23) page 1, paragraph 1 - page 2, paragraph 5 page 8, paragraph 1 claim 3 ----	1-12
Y	US 6 156 764 A (ASMUSSEN BODO ET AL) 5 December 2000 (2000-12-05) column 1, line 59 - column 3, line 4 column 3, line 18-56 column 4, line 23-35 examples 1-3 ----	1-12
A	US 5 498 636 A (GOLDBERG ARTHUR H ET AL) 12 March 1996 (1996-03-12) page 1-4 ----	1-12
A	US 5 559 111 A (YAMAGUCHI YASUCHIKA ET AL) 24 September 1996 (1996-09-24) abstract claims 8-24 ----	1-12
A	WO 00 61144 A (GROTE LUDGER ; HEDNER JAN (SE)) 19 October 2000 (2000-10-19) abstract claims 1,2 ----	1-12
A	DE 195 31 463 A (MERCK PATENT GMBH) 27 February 1997 (1997-02-27) claims 1-7 -----	1-12

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 02/11652

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 11,12 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-4, 7-12 relate to compounds defined by reference to a desirable characteristic or property, namely: "AT1-receptor antagonists having at least one acidic center", "cardiovascular ingredients having at least one basic center", "calcium channel blockers", "endothelin antagonists", "renin inhibitors", "beta-blockers", "alpha-adrenergic antagonists" and "alpha-adrenergic agonists".

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to their pharmacological profile: "AT1-receptor antagonists", "cardiovascular ingredients", "calcium channel blockers", "endothelin antagonists", "renin inhibitors", "beta-blockers", "alpha-adrenergic antagonists" and "alpha-adrenergic agonists".

Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the specific AT1-receptor inhibitor mentioned in claim 2 (valsartan), to the cardiovascular ingredient mentioned in claim 4 (amlodipine, oxprenolol and

(2S,4S,5S,7S)-5-amino-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxy-propoxy)-benzyl)-8-methyl-nonan-(2-carbamoyl-2-methyl-propyl)-amide)), and to the corresponding combination salts mentioned in claims 5 and 6.

Moreover, claim 11 relates to the treatment of a disease which actually is not well defined. The use of the definition "cardiovascular diseases and conditions" in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. It is not fully possible to determine all the diseases for which protection might legitimately be sought. The lack of clarity is such as to render a meaningful complete search impossible. Consequently the search has been restricted to the real and defined diseases mentioned in claim 12, with due regard to the general idea underlying the invention.

Claims searched completely: 5 and 6.

Claims searched incompletely: 1-4,7-12.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/11652

Patent document cited in search report		Publication date	Patent family member(s)	Publication date			
WO 0002543	A	20-01-2000	AU 753486 B2	17-10-2002			
			AU 5034999 A	01-02-2000			
			BR 9912021 A	03-04-2001			
			CA 2336822 A1	20-01-2000			
			CN 1312715 T	12-09-2001			
			WO 0002543 A2	20-01-2000			
			EP 1096932 A2	09-05-2001			
			HU 0102828 A2	29-04-2002			
			JP 2002520274 T	09-07-2002			
			NO 20010113 A	09-03-2001			
			PL 345897 A1	14-01-2002			
			SK 312001 A3	11-06-2001			
			TR 200100062 T2	21-06-2001			
			ZA 200100232 A	09-04-2002			
WO 0044378	A	03-08-2000	AU 2439700 A	18-08-2000			
			BR 0007686 A	06-11-2001			
			CA 2360691 A1	03-08-2000			
			CN 1337879 T	27-02-2002			
			CZ 20012682 A3	17-10-2001			
			WO 0044378 A1	03-08-2000			
			EP 1146872 A1	24-10-2001			
			HU 0105199 A2	29-04-2002			
			JP 2002535367 T	22-10-2002			
			NO 20013459 A	05-09-2001			
			SK 10522001 A3	03-12-2001			
			US 2002042436 A1	11-04-2002			
			WO 0240007	A	23-05-2002	AU 2368002 A	27-05-2002
						WO 0240007 A1	23-05-2002
US 6156764	A	05-12-2000	DE 19607395 A1	04-09-1997			
			AT 212024 T	15-02-2002			
			AU 712255 B2	04-11-1999			
			AU 1769597 A	16-09-1997			
			CA 2247616 A1	04-09-1997			
			CN 1212698 A ,B	31-03-1999			
			CZ 9802657 A3	11-11-1998			
			DE 59706015 D1	21-02-2002			
			DK 883619 T3	29-04-2002			
			WO 9731918 A1	04-09-1997			
			EP 0883619 A1	16-12-1998			
			ES 2171886 T3	16-09-2002			
			HU 9900568 A2	28-06-1999			
			IL 125819 A	21-04-2002			
			JP 2000505463 T	09-05-2000			
			NO 983864 A	21-08-1998			
			NZ 331485 A	29-03-1999			
			PL 328712 A1	15-02-1999			
			PT 883619 T	31-07-2002			
			SI 883619 T1	30-06-2002			
			SK 104398 A3	02-12-1998			
			ZA 9701740 A	04-09-1997			
US 5498636	A	12-03-1996	NONE				
US 5559111	A	24-09-1996	AT 183997 T	15-09-1999			
			AU 1642095 A	26-10-1995			

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/11652

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5559111	A		AU 699616 B2	10-12-1998
			AU 1642195 A	26-10-1995
			AU 1642395 A	26-10-1995
			BR 1100656 A3	06-06-2000
			CA 2147044 A1	19-10-1995
			CA 2147052 A1	19-10-1995
			CA 2147056 A1	19-10-1995
			CN 1117960 A	06-03-1996
			CZ 9500976 A3	15-11-1995
			DE 59506707 D1	07-10-1999
			DK 678503 T3	20-03-2000
			EP 0678503 A1	25-10-1995
			EP 0678514 A1	25-10-1995
			EP 0678500 A1	25-10-1995
			ES 2137478 T3	16-12-1999
			FI 951771 A	19-10-1995
			FI 951772 A	19-10-1995
			FI 951773 A	19-10-1995
			GR 3031997 T3	31-03-2000
			HU 74074 A2	28-10-1996
			HU 72110 A2	28-03-1996
			HU 71701 A2	29-01-1996
			IL 113403 A	24-07-2001
			JP 8053434 A	27-02-1996
			JP 3240322 B2	17-12-2001
			JP 8081430 A	26-03-1996
			JP 8027079 A	30-01-1996
			NO 951441 A	19-10-1995
			NO 951442 A	19-10-1995
			NO 951443 A	19-10-1995
			NZ 270936 A	24-06-1997
			NZ 270938 A	26-11-1996
			NZ 270939 A	20-12-1996
			TW 402582 B	21-08-2000
			US 5606078 A	25-02-1997
			US 5659065 A	19-08-1997
			US 5654445 A	05-08-1997
			US 5646143 A	08-07-1997
			US 5627182 A	06-05-1997
			US 5705658 A	06-01-1998
			ZA 9503050 A	08-11-1995
			ZA 9503051 A	18-10-1995
			ZA 9503052 A	18-10-1995
WO 0061144	A	19-10-2000	AU 4322900 A	14-11-2000
			WO 0061144 A1	19-10-2000
DE 19531463	A	27-02-1997	DE 19531463 A1	27-02-1997